Esketamine safe, effective for treatment-resistant depression

January 4, 2018

(HealthDay)—Esketamine seems to be efficacious and safe for patients with treatment-resistant depression (TRD), according to a study published online Dec. 27 in JAMA Psychiatry.

Ella J. Daley, M.D., from Janssen Research & Development LLC in Titusville, N.J., and colleagues conducted a phase 2, double-blind, doubly randomized, delayed-start, placebo-controlled study to examine the efficacy, safety, and dose-response of intranasal esketamine hydrochloride. A total of 67 adults with a diagnosis of and history of inadequate response to two or more antidepressants (TRD) were randomized and 60 completed two one-week double-blind treatment periods. In period 1, participants were randomized to placebo or esketamine 28, 56, or 84 mg twice weekly (33, 11, 11, and 12 participants, respectively). In period 2, 28 placebo-treated participants were re-randomized to one of the four treatment arms.

The researchers found that the change in Montgomery-Åsberg Depression Rating Scale total score was superior in all three esketamine groups versus placebo (least squares mean difference versus placebo: esketamine 28 mg: −4.2; 56 mg: −6.3; 84 mg: −9.0), with a significant ascending dose-response relationship. Despite reduced dosing frequency in the open-label phase, the improvement in depressive symptoms appeared to be sustained (−7.2).

"In this first clinical study to date of intranasal esketamine for TRD, antidepressant effect was rapid in onset and dose-related," the authors write. "Results support further investigation in larger trials."

Several authors disclosed financial ties to Janssen Research & Development LLC, which funded the study.

Explore further: Opicapone as levodopa adjunct cuts motor fluctuations in Parkinson's disease

More information: Abstract/Full Text
Editorial (subscription or payment may be required)

Related Stories

Opicapone as levodopa adjunct cuts motor fluctuations in Parkinson's disease

December 28, 2016
(HealthDay)—For patients with Parkinson's disease (PD) receiving levodopa therapy and experiencing end-of-dose motor fluctuations, treatment with 50-mg/day opicapone is associated with a reduction in mean daily off-time, ...

Varenicline linked to reduction in heavy drinking in men

December 21, 2017
(HealthDay)—Varenicline is associated with reduced heavy drinking among men and with increased smoking abstinence, according to a study published online Dec. 20 in JAMA Psychiatry.

Intranasal omalizumab does not increase serum IgE levels

November 22, 2017
(HealthDay)—In patients with birch pollen allergy, intranasal administration of omalizumab does not result in relevant change of allergen-specific and total immunoglobulin E (IgE) levels, according to a pilot study published ...

Secukinumab effective for moderate / severe scalp psoriasis

September 29, 2017
(HealthDay)—Secukinumab is safe and effective as a treatment for patients with extensive moderate-to-severe scalp psoriasis, according to a study published in the October issue of the Journal of the American Academy of ...

Naloxegol has no effect on opioid dose in opioid-tied constipation

September 21, 2017
(HealthDay)—For patients with noncancer pain and opioid-induced constipation (OIC), naloxegol has no clinically relevant effect on patient-reported pain levels or mean daily opioid dose, according to research published ...

Lisdexamfetamine dimesylate has early benefit in binge eating

August 4, 2017
(HealthDay)—Lisdexamfetamine dimesylate (LDX) is associated with early improvement in efficacy measures in adults with binge-eating disorder (BED), according to research published in the August issue of the International ...

Recommended for you

People can handle the truth (more than you think)

September 19, 2018
Most people value the moral principle of honesty. At the same time, they frequently avoid being honest with people in their everyday lives. Who hasn't told a fib or half-truth to get through an awkward social situation or ...

Mindfulness meditation: 10 minutes a day improves cognitive function

September 19, 2018
Practising mindfulness meditation for 10 minutes a day improves concentration and the ability to keep information active in one's mind, a function known as "working memory". The brain achieves this by becoming more efficient, ...

Close intercultural romantic relationships and friendships can boost creativity

September 19, 2018
You've worked abroad. You've lived abroad. But have you had a close friendship or romantic relationship with a person from a culture drastically different from your own?

Study reveals cannabinoid drugs make pain feel 'less unpleasant, more tolerable'

September 19, 2018
Researchers in the College of Arts and Sciences have determined that cannabinoid drugs do not appear to reduce the intensity of experimental pain, but, instead, may make pain feel less unpleasant and more tolerable.

The 'real you' is a myth – we constantly create false memories to achieve the identity we want

September 19, 2018
We all want other people to "get us" and appreciate us for who we really are. In striving to achieve such relationships, we typically assume that there is a "real me". But how do we actually know who we are? It may seem simple ...

New research helps to instill persistence in children

September 19, 2018
Encouraging children "to help," rather than asking them to "be helpers," can instill persistence as they work to fulfill daily tasks that are difficult to complete, finds a new psychology study.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.